Rethinking HEOR Market Access Integration: A Ca...

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must o...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Pfizer Trump Drug Prices: A Landmark Deal for Affordable Medications
Sanofi Insulin Savings: Your Comprehensive Guide for 2025
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals
Biosimilars Market Trends 2025: Understanding Erosion and Growth
Mounjaro Price Increase UK: Impacts on Access and Health Economics
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...